Evidence map›Paper›PMID 31160585›Full record

ArticleNature communications2019

Lysine 68 acetylation directs MnSOD as a tetrameric detoxification complex versus a monomeric tumor promoter.

Yueming Zhu, Xianghui Zou, Angela E Dean, Joseph O' Brien, Yucheng Gao, Elizabeth L Tran, Seong-Hoon Park, Guoxiang Liu, Matthew B Kieffer, Haiyan Jiang and 7 more

Open access · goldAbstract read
In one paragraph

Article in Nature communications, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed
2.2field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 60 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. The curious life of human mitochondrial SOD2.International journal of biological macromolecules · 2026
    Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Insights into Manganese Superoxide Dismutase and Human Diseases.International journal of molecular sciences · 2022
    Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 3 institutions in 2 countries.

Yueming ZhuDepartment of Radiation Oncology, Feinberg School of Medicine, Northwestern University, Chicago, IL, 60611, USA.
Xianghui ZouDepartment of Radiation Oncology, Feinberg School of Medicine, Northwestern University, Chicago, IL, 60611, USA.
Angela E DeanDepartment of Radiation Oncology, Feinberg School of Medicine, Northwestern University, Chicago, IL, 60611, USA.
Joseph O' BrienDepartment of Radiation Oncology, Feinberg School of Medicine, Northwestern University, Chicago, IL, 60611, USA.
Yucheng GaoDepartment of Radiation Oncology, Feinberg School of Medicine, Northwestern University, Chicago, IL, 60611, USA.
Elizabeth L TranDepartment of Radiation Oncology, Feinberg School of Medicine, Northwestern University, Chicago, IL, 60611, USA.
Seong-Hoon ParkDepartment of Radiation Oncology, Feinberg School of Medicine, Northwestern University, Chicago, IL, 60611, USA.
Guoxiang LiuDepartment of Radiation Oncology, Feinberg School of Medicine, Northwestern University, Chicago, IL, 60611, USA.
Matthew B KiefferDepartment of Microbiology-Immunology, Feinberg School of Medicine, Northwestern University, Chicago, IL, 60611, USA.ORCID http://orcid.org/0000-0003-4890-3068
Haiyan JiangDepartment of Radiation Oncology, Feinberg School of Medicine, Northwestern University, Chicago, IL, 60611, USA.
Melissa E StaufferScientific Editing Solutions, Walworth, WI, 53184, USA.
Robert HartDepartment of Medicine, University of Illinois at Chicago, Chicago, IL, 60612, USA.
Songhua QuanDepartment of Radiation Oncology, Feinberg School of Medicine, Northwestern University, Chicago, IL, 60611, USA.
Karla J F SatchellDepartment of Microbiology-Immunology, Feinberg School of Medicine, Northwestern University, Chicago, IL, 60611, USA.ORCID http://orcid.org/0000-0003-3274-7611
Nobuo HorikoshiDepartment of Radiation Oncology, Feinberg School of Medicine, Northwestern University, Chicago, IL, 60611, USA.
Marcelo BoniniDepartment of Medicine, University of Illinois at Chicago, Chicago, IL, 60612, USA.
David GiusDepartment of Radiation Oncology, Feinberg School of Medicine, Northwestern University, Chicago, IL, 60611, USA. david.gius@northwestern.edu.
Northwestern University · USUniversity of Illinois Chicago · USScientific Solutions (United States) · US

Funding

Tumor Environment and Metastasis (TEAM) Research ProgramP30CA060553 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI Daniela E Matei · 1993 to 2026
$153.9M
TRANSGENIC COREP30AG013319 · NIA · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI PETER J HORNSBY · 1995 to 2026
$30.6M
TR&D 7: Cell Specific ProteomicsP41GM108569 · NIGMS · NORTHWESTERN UNIVERSITY · PI KELLEHER, NEIL L · 2015 to 2024
$13.6M
Molecular mechanism of V. vulnificus MARTX toxin in pathogenesis and food safetyR01AI092825 · NIAID · NORTHWESTERN UNIVERSITY AT CHICAGO · PI SATCHELL, KARLA J F · 2011 to 2021
$4.1M
Loss of mtSIRT3, Decreased MnSOD Activity, and IR Induced Genomic InstabilityR01CA152601 · NCI · VANDERBILT UNIVERSITY · PI BONINI, MARCELO G. · 2010 to 2019
$3.5M
New Strategies for Treating Septic Vasculopathy Inflammation and ThrombosisR01HL125356 · NHLBI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI BONINI, MARCELO G., DU, XIAOPING · 2014 to 2018
$3.4M
MnSOD-K68-Ac reprograms a lineage plasticity switch / stemness in ER+ breast malignancies.R01CA253678 · NCI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI GIUS, DAVID · 2021 to 2025
$2.1M
Dys-regulation of the MnSOD-Ac-ROS-HIF2a axis promotes IR / Cisplatin resistance phenotypeR01CA214025 · NCI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI GIUS, DAVID · 2017 to 2021
$2.0M
Lineage Plasticity, due to Disruption of MnSOD Biology, drives resistance to Ionizing Radiation / Androgen Deprivation TherapyR01CA257148 · NCI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI GIUS, DAVID · 2021 to 2025
$2.0M
ROS and HIFa as molecular targets for chemoprevention in Sirt3 -/- breast cancersR01CA168292 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI GIUS, DAVID · 2012 to 2016
$1.9M
SIRT3 is a Mitochondrial Tumor Suppressor in ER/PR Positive Mammary TumorsR01CA152799 · NCI · VANDERBILT UNIVERSITY · PI GIUS, DAVID · 2011 to 2015
$1.6M
NCI NIH HHS P30 CA060553NCI NIH HHS R01 CA152601NCI NIH HHS R01 CA152799NCI NIH HHS R01 CA168292NCI NIH HHS R01 CA214025NCI NIH HHS R01 CA253678NCI NIH HHS R01 CA257148NHLBI NIH HHS R01 HL125356NIAID NIH HHS R01 AI092825NIA NIH HHS P30 AG013319NIGMS NIH HHS P41 GM108569
6 · The paper itself

Abstract

Manganese superoxide dismutase (MnSOD) functions as a tumor suppressor; however, once tumorigenesis occurs, clinical data suggest MnSOD levels correlate with more aggressive human tumors, implying a potential dual function of MnSOD in the regulation of metabolism. Here we show, using in vitro transformation and xenograft growth assays that the MnSOD-K68 acetylation (Ac) mimic mutant (MnSOD

Indexed as

AcetylationAnimalsAntineoplastic Agents, HormonalBreast NeoplasmsCarcinogenesisCell Line, TumorDisease ProgressionDrug Resistance, NeoplasmHumansIn Vitro TechniquesLysineMCF-7 CellsMiceMutationNeoplasm TransplantationPeroxidaseAntineoplastic Agents, HormonalLysinePeroxidaseReactive Oxygen SpeciesSuperoxide DismutaseTamoxifenTumor Suppressor Proteins

Identifiers

PMID31160585
PMCPMC6546705
OpenAlexW2948741997

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.